PCVX Form 4: Jim Wassil Reports Share Surrenders and Divorce Transfer
Rhea-AI Filing Summary
Vaxcyte, Inc. Chief Operating Officer Jim Wassil reported multiple dispositions of Vaxcyte common stock on a Form 4. On 09/02/2025 he surrendered 1,270, 1,587 and 1,429 shares (each at $31.56) to cover tax withholding upon RSU vesting, reducing reported holdings in successive lines to 149,286, 147,699 and 146,270 shares respectively. The filing also discloses a prior transfer of 1,689 shares to an ex-spouse pursuant to a divorce settlement on April 1, 2025, and notes 329 shares acquired under the Employee Stock Purchase Plan on May 16, 2025. The Form is signed by attorney-in-fact and dated 09/04/2025.
Positive
- Form filed and signed, indicating compliance with Section 16 reporting requirements
- Transactions are documented as tax withholding and a domestic relations order, providing clear explanations for share reductions
Negative
- Reported reductions in beneficial ownership including share surrenders of 1,270, 1,587 and 1,429 shares on 09/02/2025
- Prior transfer of 1,689 shares to an ex-spouse pursuant to a divorce settlement on April 1, 2025
Insights
TL;DR: Routine insider tax-withholding share surrenders and a prior divorce-related transfer; filing documents compliance and ownership changes.
The Form 4 shows common administrative actions rather than discretionary open-market sales: three share surrenders on 09/02/2025 at $31.56 each expressly to cover tax withholding on vested RSUs, and an earlier transfer of 1,689 shares under a domestic relations order executed April 1, 2025. These items change reported beneficial ownership but are non-operational in nature. The filing was executed by an attorney-in-fact and dated 09/04/2025, indicating timely reporting. For investors, the transactions clarify current insider holdings but do not convey new company developments.
TL;DR: Dispositions are tax and legal-ordered transfers; no evidence of material insider-driven liquidity event in this filing.
The disposition line items (1,270; 1,587; 1,429 shares) are explicitly described as shares surrendered to cover tax withholding from vested RSUs. The separate disclosure of a domestic relations order transferring 1,689 shares on April 1, 2025, further explains reductions unrelated to trading intent. The filing documents remaining beneficial ownership amounts at each reporting line and an Employee Stock Purchase Plan allocation of 329 shares, providing clear, transaction-level transparency. Impact on valuation appears limited based on the nature and scale disclosed here.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock | 1,270 | $31.56 | $40K |
| Tax Withholding | Common Stock | 1,587 | $31.56 | $50K |
| Tax Withholding | Common Stock | 1,429 | $31.56 | $45K |
Footnotes (1)
- Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. The Reporting Person entered into a divorce settlement agreement with his ex-spouse (the Settlement Agreement") pursuant to a "domestic relations order" as defined in Section 16(a)(12) of the Securities Exchange Act of 1934, as amended. On April 1, 2025, the Reporting Person transferred 1,689 shares of Vaxcyte, Inc. Common Stock to his ex-spouse pursuant to the Settlement Agreement. Accordingly, the Reporting Person will not report beneficial ownership of or dispositions of the disposed shares in future Section 16(a) filings. Includes 329 shares acquired under the Issuer's Employee Stock Purchase Plan on May 16, 2025.
